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Coil-Assisted Retrograde Transvenous Obliteration
(CARTO) for the Treatment of Portal Hypertensive
Variceal Bleeding: Preliminary Results
Edward W. Lee, MD, PhD1, Sammy Saab, MD2, Antoinette S. Gomes, MD1, Ronald Busuttil, MD, PhD3, Justin McWilliams, MD1,
Francisco Durazo, MD2, Steven-Huy Han, MD2, Leonard Goldstein, MD2, Bashir A. Tafti, MD1, John Moriarty, MD1,
Christopher T. Loh, MD1 and Stephen T. Kee, MD1
OBJECTIVES: To describe the technical feasibility, safety, and clinical outcomes of coil-assisted retrograde transvenous
obliteration (CARTO) in treating portal hypertensive non-esophageal variceal hemorrhage.
METHODS: From October 2012 to December 2013, 20 patients who received CARTO for the treatment of portal hypertensive non-
esophageal variceal bleeding were retrospectively evaluated. All 20 patients had at least 6-month follow-up. All patients had
detachable coils placed to occlude the efferent shunt and retrograde gelfoam embolization to achieve complete thrombosis/
obliteration of varices. Technical success, clinical success, rebleeding, and complications were evaluated at follow-up.
RESULTS: A 100% technical success rate (defined as achieving complete occlusion of efferent shunt with complete thrombosis/
obliteration of bleeding varices and/or stopping variceal bleeding) was demonstrated in all 20 patients. Clinical success rate
(defined as no variceal rebleeding) was 100%. Follow-up computed tomography after CARTO demonstrated decrease in size with
complete thrombosis and disappearance of the varices in all 20 patients. Thirteen out of the 20 had endoscopic confirmation of
resolution of varices. Minor post-CARTO complications, including worsening of esophageal varices (not bleeding) and worsening
of ascites/hydrothorax, were noted in 5 patients (25%). One patient passed away at 24 days after the CARTO due to systemic and
portal venous thrombosis and multi-organ failure. Otherwise, no major complication was noted. No variceal rebleeding was noted
in all 20 patients during mean follow-up of 384± 154 days.
CONCLUSIONS: CARTO appears to be a technically feasible and safe alternative to traditional balloon-occluded retrograde
transvenous obliteration or transjugular intrahepatic portosystemic shunt, with excellent clinical outcomes in treating portal
hypertensive non-esophageal variceal bleeding.
Clinical and Translational Gastroenterology (2014) 5, e61; doi:10.1038/ctg.2014.12; published online 2 October 2014
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INTRODUCTION
Traditional balloon-occluded retrograde transvenous oblitera-
tion (BRTO) is a well-accepted method of treating gastric
variceal bleeding (GVB) in the setting of portal hypertension,
with a very high clinical success rate of 95% of ceasing
variceal bleeding.1–10 It is even more valuable when consider-
ing that GVB is associated with a higher mortality rate and
poorer outcomes, as endoscopic treatment or conservative
management are ineffective in treating GVB.11–15 With an
increased incidence of GVB, due to effective endoscopic
treatment of esophageal varices redistributingmore portal flow
toward the gastric varices, BRTO becomes an attractive
addition to the armamentarium to treat GVB.
Currently, BRTO requires the use of an indwelling occlusive
balloon inflated for hours with injection of sclerosing agents
such as ethanolamine oleate or sodium tetradecal sulfate to
cause sclerosis of varices and efferent shunts. An indwelling
inflated balloon results in lengthy procedure times, additional
hospital resources, and logistics (e.g., intensive care unit bed,
additional patient transport, additional interventional radiology
suite time, and staff) and the innate complications associated
with balloons (e.g., balloon rupture). The sclerosing agents are
also associated with some of the serious complications of
BRTO, including: pulmonary edema, disseminated intravas-
cular coagulation, portal vein thrombosis, severe renal
dysfunction, and anaphylactic reaction.3,4,9,16–24
Recently, modified BRTO was proposed and reported by
Gwon et al.,25 where an indwelling balloon was replaced with a
vascular plug to minimize some of the complications and
logistical issues associated with the balloon. However, it has
its own limitations (e.g., size limit). In this study, we describe a
novel method of performing modified BRTO with coils and
gelfoam (coil-assisted retrograde transvenous obliteration
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(CARTO)) instead of indwelling balloons or vascular plugs and
sclerosing agents. The aim of the study is to evaluate the short
and long-term safety and effectiveness of CARTO in the treat-
ment of non-esophageal variceal bleeding, including GVB.
METHODS
Patient demographics. This retrospective study was
approved by the institutional review board. We retrospectively
reviewed medical records in 43 patients who received modified
BRTO between October 2012 and December 2013. Forty-three
patients underwent some type of BRTO for variceal bleeding
and/or hepatic encephalopathy. All 43 patients demonstrated
either gastrorenal or splenorenal shunt, which was accessible
from the renal vein. The patients without an appropriate shunt
received transjugular intrahepatic portosystemic shunt (TIPS;
n= 5). Of the 43, 20 who had undergone CARTO for the
treatment of acute or recent variceal bleeding were included
in this study. Of the rest of the 43 patients not included in this
study, 15 patients received CARTO for the treatment of
hepatic encephalopathy and 8 patients received PARTO
(Plug-assisted Retrograde Transvenous Obliteration) for the
treatment of GVB. The entry criterion was follow-up of
≥6 months. All the 20 patients had recorded follow-up data
of at least 6 months. Demographic, clinical, and laboratory
data were collected and reviewed retrospectively. Thirteen
out of the 20 patients had an endoscopic evaluation con-
firming an active bleeding site or stigmata of recent bleeding/
pending rupture. Seventeen out of the 20 patients had recent
preprocedural triple-phase computed tomography (CT) or
magnetic resonance imaging, with evidence supporting the
presence of efferent gastrorenal shunt. All the 20 patients had
recorded follow-up data of at least 6 months, which included
CT and/or endoscopy and clinic visits.
Technique of CARTO. An illustration of CARTO procedure
is shown in Figure 1. All CARTO procedures were performed
with moderate sedation, except for three patients who
required general anesthesia due to hemodynamic instability,
caused by acute hypotensive crisis. Prior to CARTO
procedure, a triple- or dual-phase contrast-enhanced CT of
the abdomen was reviewed to confirm the presence and size
of an efferent shunt-draining varices to the systemic venous
circulation. After preprocedural planning with CT images,
either the right internal jugular or right common femoral
venous access was achieved. An 8 or 14 Fr vascular sheath
(Cook Inc. Bloomington, IN) was placed in the inferior vena
cava or renal vein for stable access. Using a 0.035 glidewire
and 4 or 5 Fr glide or C2 catheter, the efferent shunt was
accessed. The catheter was exchanged with an occlusion
balloon (Fogarty or Equalizer balloon), and a balloon-
occluded retrograde venogram was performed to assess
and confirm the varices and the size of the shunt. After
removing the balloon, the efferent shunt was accessed using
a double microcatheter system (Figure 2) with a combination
of Renegade STC (Boston Scientific Co., Natick, MA) and
Renegade Hi-Flo (Boston Scientific Co.) with either 0.014 or
0.016 microwires. The Renegade Hi-Flo microcatheter was
advanced distally into or adjacent to the gastric varices to
perform a variceal/shunt venogram and to perform Gelfoam
embolization (Figure 2a). Through the more proximally
placed microcatheter within the efferent shunt, correctly sized
detachable coils (Interlock detachable coils, Boston Scientific
Co.; average 11.1±5.3, range 5–22) were deployed, and
complete occlusion of the efferent shunt was confirmed with a
venogram (Figure 2a). Then, through the distally placed
microcatheter, gelfoam (gelfoam sponge sizes from approxi-
mately 2 to 5 mm3) mixed with contrast agent was injected to
embolize the entire efferent shunt, varices, collaterals, and
afferent veins (average number of Gelfoam packs= 6.3± 3.5
packs, range 3–13 packs) (Figure 2b). Postembolization
venography was performed using the distally placed
microcatheter again to confirm complete occlusion of the
efferent shunt and complete stasis within the varices.
After venographic confirmation of completion, the microcath-
eters were removed. During the procedure, the patient’s
blood pressure, pulse, electrocardiogram, and arterial
oxygen saturation were monitored. Serial laboratory values,
including liver function tests, complete blood counts, and
ammonia, were monitored until discharge. All patients
had a triple-phase contrast-enhanced CT of the abdomen
within 2–3 days prior to discharge to evaluate: (1) oblite-
ration of the efferent shunt and gastric varices, and (2)
evidence of immediate complications, including renal vein
thrombosis, inferior vena cava thrombosis, or portal vein
thrombosis. All patients were clinically assessed for pulmon-
ary embolism.
Upon discharge, all 20 patients underwent 1-, 3- and/or 6-
month triple-phase CTand/or follow-up upper gastrointestinal
endoscopy. Follow-up clinical and laboratory data were
collected from all 20 patients and reviewed.
Figure 1 An illustration of coil-assisted retrograde transvenous obliteration
(CARTO) procedure. This illustration demonstrates complete obliteration/thrombosis
of GV and GRS (in black color) post-CARTO procedure after deploying multiple coils
in the GRS and filling the GRS and GV via retrograde fashion using gelfoam slurry.
Coils, coils in the GRS; GRS, gastrorenal shunt; GV, gastric varices; IMV, inferior
mesenteric vein; IVC, inferior vena cava; L, Liver; LGV, left gastric vein (coronary
vein); LK, left kidney; LRV, left renal vein; PV, portal vein; S, Stomach; SMV, superior
mesenteric vein; Sp, Spleen; SpV, splenic vein.
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Definitions and statistical analysis. Technical success
was defined as successfully achieving complete occlusion
of efferent shunts using embolization coils with complete
gelfoam-induced thrombosis/obliteration of bleeding varices
and/or immediate stopping of variceal bleeding. Clinical
success was defined as the lack of variceal rebleeding in
any clinical follow-up, including endoscopically visualized
bleeding or clinical evidence of hematemesis, hematochezia,
or melena. Complete thrombosis/obliteration of the varices
was defined as the complete disappearance of targeted
varices, as seen on follow-up CT or endoscopy 1 month
following CARTO or at any time thereafter. Complications
were classified as “major” and “minor” according to the
guidelines of the Society of Interventional Radiology Stan-
dards of Practice Committee.26 “Minor” complications were
defined as those requiring no or nominal therapy, including
overnight admission for observation only. “Major” complica-
tions were defined as those necessitating major therapy, an
unplanned increase in the level of care or prolonged
hospitalization (448 h), or those resulting in permanent
adverse sequelae or death.
Paired-sample t-test was used to compare pre- and post-
CARTO serum ammonia levels. The statistical analysis was
performed using the SPSS software (version 15.0. SPSS,
Chicago, IL), with P-values o0.05 considered to be statisti-
cally significant.
RESULTS
Patients. There were 12 men and 8 women with a mean age
of 58 years (range 17–75 years). The indications for CARTO
were GVB (n= 14), stomal variceal bleeding (n=3), duodenal
variceal bleeding (n= 1), jejunal variceal bleeding (n=1), and
rectal variceal bleeding (n=1). Seven patients presented with
acute variceal bleeding and 13 patients had a history of
recent bleeding within 3 months at the time of presentation.
Table 1 summarizes patient demographics.
Technical outcomes. Successful coil occlusion of efferent
shunt with complete gelfoam embolization and thrombosis of
the shunt was achieved in all 20 patients and was confirmed
with post-CARTO venography in all the patients. Fifteen
patients received CARTO via transfemoral approach and five
patients received transjugular approach. The mean proce-
dure time from venous access to the end of procedure
Figure 2 Fluoroscopic images of coil-assisted retrograde transvenous obliteration (CARTO). (a) A double microcatheter system with the proximal microcatheter (black
arrowhead) is used for coil deployment, and the distal microcatheter (black arrow) is used for gelfoam injection and gastric variceal (GV) and gastrorenal shunt (GRS) venogram.
Multiple detachable coils (white arrow) are used in place of an indwelling occlusive balloon used in a conventional balloon-occluded retrograde transvenous obliteration.
(b) Technically successful CARTO demonstrating complete stasis and opacification of GRS (white arrow) and GV (black arrow).
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(removal of sheath and start of venotomy hemostasis with
manual compression) was 2.82±0.56 h. Technical success
was achieved in all 20 patients with complete resolution of
variceal bleeding during immediate follow-up by both clinical
(hemodynamic stability, no transfusion requirement, no
hematemesis, or melena) and radiological (CT evidence of
disappearance of shunt and varices) evidence (technical
success rate=100%).
Seven patients presented with severe hypotension requiring
2–3 vasopressors at the beginning of the procedure. However,
their hemodynamic status normalized at the end of procedure
or within a day after the procedure. No procedure-related
immediate complications or death were identified in any
patients. However, one patient passed away at 24 days post-
CARTO with severe systemic venous thrombosis and multi-
organ failure (n=1).
Clinical outcomes. Clinical success rate was 100%. Com-
plete thrombosis of the efferent shunts and varices were seen
in all the patients as early as 2 days after CARTO, and
sequential disappearance of targeted varices was noted at 1-,
3-, and 6-month follow-up CTs in 19 patients (Figure 3). 8/20
patients had a 1-year follow-up CT with consistent resolution
of varices. In all, 13/20 patients also underwent periodic
endoscopic follow-up at 1, 2, 3, and/or 6 months and showed
complete resolution of intra-luminal gastric varices (Figure 4).
No patients had clinical symptoms related to variceal
bleeding such as hemodynamic instability, decreasing hemo-
globin, hematemesis, anemia or melena, except for one
patient who had asymptomatic anemia (H/H= 5.8/19.9 from
8.0/27.6) discovered incidentally during a regular hepatology
visit. He was transfused with packed red blood cell without
further anemia, and no etiology of anemia was found follow-
ing a full evaluation.
Transient increase in serum total bilirubin (TBili) level
was noted in 12 patients with normalizing or down-trending
levels within 2 days and complete normalization at
1 month follow-up in 10 patients. The mean pre-CARTO TBili
in 10 patients was 1.3±0.6 and post-CARTO TBili was
1.5± 0.6 at 2 days and 1.2±0.5 at 1 month. Two patients had
increased and persistently elevated TBili at 1 month without
improvement. Both patients had higher baseline TBili values
of 2.8 and 6.7 mg/dl, respectively. Conversely, eight patients
Table 1 Patient characteristics
Patient demographics
Male: female 12: 8
Age (years) 58 (17–75)
Underlying liver disease
Alcoholic cirrhosis 6 (30.0%)
Hepatitis C cirrhosis 6 (30.0%)
Hepatitis B cirrhosis 3 (15.0%)
Cryotogenic cirrhosis 2 (10.0%)
Primary sclerosing cholangitis cirrhosis 2 (10.0%)
Non-alcoholic steatohepatitis 1 (5.0%)
Pre-CARTO MELD 12.2±5.2
Concomitant malignancy
Hepatocellular carcinoma 1 (5.0%)
Metastatic neuroendocrine tumor 1 (5.0%)
CARTO, coil-assisted retrograde transvenous obliteration; MELD, model for
end-stage liver disease.
Figure 3 Contrast-enhanced portal-venous phase axial computed tomography images of gastric varices in (a) pre-CARTO (pre-coil-assisted retrograde transvenous
obliteration) with huge transmural gastric variceals (GVs) in the gastric fundus with a recent history of acute upper gastrointestinal bleeding, (b) Two-day post-CARTO
demonstrating non-enhancing/hypoenhancing gastric fundal wall consisted with completely thrombosed GV, (c) 1-month post-CARTO demonstrating mild mucosal
hypoenhancement of gastric fundus without evidence of GVs, and (d) 6-month post-CARTO showing complete disappearance of GVs with normal gastric fundal enhancement/
anatomy.
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had immediate improvement in TBili at 2 days and
of these eight, six patients had persistently improved TBili at
1 month.
Of note, the mean serum ammonia level in patients tested
(n= 12) pre-CARTO was 124.5±35.2 and post-CARTO was
91.0±28.7 at 2 days and 77.1± 14.0 at 1 month. Table 2
demonstrates serum Tbili level changes over the course of
follow-up.
Follow-up and complications. The mean follow-up period
was 384±154 days (range 24–622 days). Of the 13 patients
who had known esophageal varices, 3 had endoscopic
evidence of worsened esophageal varices compared with
pre-CARTO evaluation. However, to date, no patients have
experienced esophageal variceal bleeding. Of the 20
patients, 4 patients had episodes of upper gastrointestinal
bleeding during the follow-up, which were all caused by portal
hypertensive gastropathy without variceal bleeding (20%).
Five patients had new ascites/hydrothorax or worsened
ascites after CARTO (25%). One patient passed away at
24 days with a diagnosis of systemic and portal venous
thrombosis and multi-organ failure. Otherwise, no evidence of
portal or splenic vein thrombosis, renal vein or caval
thrombosis, renal failure, or pulmonary embolization
was observed in 19 patients. No patients showed signs of
hepatic encephalopathy. Nineteen patients are alive as of
June 2014.
DISCUSSION
In this study, we demonstrated that BRTO/CARTO can
effectively treat portal hypertensive variceal bleeding, includ-
ing GVB, without using an indwelling balloon catheter. Without
an indwelling balloon catheter, we were able to modify and
perform CARTO in 20 patients with immediate cessation
of variceal bleeding. Our study showed that CARTO can
achieve a technical success rate of 100% and a clinical
success rate of 100% at 6-month follow-up in 19 patients,
which is concordant with previously reported results for
conventional BRTO and modified BRTO.1–3,7–10,17,25–38
CARTO was successfully used to treat any non-esophageal
variceal bleeding, including gastric, duodenal, jejunal, and
stomal variceal bleeding.
The indwelling balloon in BRTO performs two functions: (1)
it provides complete stasis within the gastrorenal shunt to
promote sclerosis, and hence it promotes thrombosis of the
shunt and varices, and (2) it provides complete blockage of
gastrorenal shunt flow into the systemic circulation to prevent
any sclerosant leakage. However, due to long balloon
indwelling time (4–48 h), the indwelling balloon may be a
nidus for complications such as increased risk of balloon
rupture, access site complications, and infection, as well as
logistical challenges for hospitals such as patient discomfort/
inconvenience, intensive care unit or higher level monitored
bed requirement, and additional staff.1–3,7–10,17,25–38
Figure 4 Endoscopic images of the gastric fundus. (a) Pre-CARTO (pre-coil-assisted retrograde transvenous obliteration) image demonstrating massive gastric variceals
(GVs; white circle) in the gastric fundus with red spots, stigmata of recent bleeding, and (b) 6-month post-CARTO image demonstrating complete resolution of previously
seen GVs.
















(n=20, p = 0.50)
1.46 ± 0.81
(n=19, p = 0.21) 
1.23 ± 0.66
(n=19, p = 0.07) 
Abbreviations: CARTO, coil-assisted retrograde transvenous obliteration; TBili,
total bilirubin.
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Therefore, it inevitably increases the periprocedural/postpro-
cedural cost. Some of these issues were resolved with a
recently proposed modified BRTO using a vascular plug.25 By
using a more permanent vascular occlusive device, the
vascular plug, the complications and logistical issues with
an indwelling balloon catheter are successfully resolved.
However, the vascular plug has its own limitations, including
(1) the fact that the vascular plug may not create complete
occlusion of a large gastrorenal shunt with very rapid blood
flow due to its mesh material, and (2) the vascular plug is only
available up to 22mm, which can block gastrorenal shunts
with diameters up to 16–18mm, but cannot be used for larger
sizes. In our experience, coils can be used for shunts
measuring up to 25–30mm size, and with enough coils, a
complete occlusion can be achieved without leakage. Like the
vascular plug, coils also create permanent vascular occlusion
while avoiding some of the complications and challenges
associated with BRTO and its usage of indwelling balloon
catheters.
In addition to replacing indwelling balloon catheters with
detachable coils, we also used gelfoam slurry instead of
sclerosing agents to reduce some of the previously reported
serious complications associated with BRTO using sclerosing
agents. These include death, pulmonary embolism, pulmon-
ary edema, portal vein and/or splenic vein thrombosis, renal
vein thrombosis, renal failure, and anaphylactic reac-
tion.3,4,9,16–24 In our study, although we had one death post-
CARTO, which is likely due to the patient’s underlying liver
disease and co-morbilities (multiple medical problems, includ-
ing chronic renal failure and diabetes), we had no major
complications associated with gelfoam slurry. One can argue
that gelfoam slurry in the gastrorenal shunt and gastric varices
may have triggered a cascade of hypercoagulapathy in this
patient that may have led to systemic and portal venous
thrombosis. However, the gelfoam has been utilized in other
numerous embolization studies in our institution and have not
shown to trigger such complications. Unfortunately, we were
unable to prove this patient’s hypercoagulable state as the
patient’s family refused a postmortem autopsy. Physiologically
expected complications of BRTO were noted in a small
number of patients who underwent CARTO, including tran-
sient elevation of liver function tests, including TBili and
worsening of ascites and/or hydrothorax. The liver function
tests have normalized to baseline levels in all the patients
except for 2 patients who had relatively higher levels of initial
TBili prior to the CARTO procedure. No patients developed
hepatic encephalopathy, which is commonly associated with
TIPS placement, an alternative treatment for variceal bleed-
ing. Due to re-direction of portal flow from gastric varices to
esophageal varices after CARTO/BRTO, several patients had
endoscopically visualized enlarged esophageal varices, but
no patient has experienced esophageal variceal bleeding at
the time of review. In their 10-year follow-up study, Akahoshi
et al.2 demonstrated up to 30% esophageal bleeding
after BRTO.
The short- and long-term follow-up clinical data for CARTO
is acceptable in our cohort. The rebleeding rate is the most
important clinical parameter for the treatment of gastric varices
as it is associated with a high mortality rate. In our study with a
limited sample size, CARTO demonstrated a 0% rebleeding
rate at 1 year in 8 patients and at 6 months in 11 patients. This
is comparable to previously reported outcomes from Asia with
traditional BRTO.2,3,8,10,17,25,26,29,30,33–36 Four patients with
episodes of upper gastrointestinal bleeding were found to
have portal hypertensive gastropathy and demonstrated slow
oozing from the gastric lumenwithout variceal bleeding. These
patients were all conservatively managed. As it appears,
CARTO may have survival benefits in these selected patients
with acute variceal bleeding. All the 19 patients are alive, and
11 patients remain on the liver transplant list at our institution
at the time of manuscript submission. This survival benefit
should be further evaluated with larger sample sizes and
longer follow-up.
At our institution, any patients with active upper gastro-
intestinal bleeding would receive an upper endoscopy first to
identify the location of bleeding source. Once it is found to be a
GVB, the abdominal CT is utilized to identify the gastrorenal
shunt, and CARTO would be performed to stop the bleeding.
Especially in patients with a high model for end-stage liver
disease (MELD) score (419), isolated GVB, and high
probability or fear of hepatic encephalopathy, CARTO is a
preferred treatment method. However, in patients with
simultaneous esophageal and GVB that is not controlled with
endoscopic treatment, TIPS is considered.
Our study has some limitations. Due to its retrospective
nature, the conclusion and outcomes of this study could
be subject to bias and are not as definitive as a prospective
trial. However, this study’s purpose is to report a novel
technique that may be added to our current armamentarium
of treating patients with portal hypertension and the
sequelae of variceal bleeding. Although only 20 patients were
evaluated, based on our results, this technique appears to be
an excellent alternative to currently practiced traditional BRTO
or modified BRTO. Additional studies such as a multi-
centered, randomized controlled trial may be performed to
further evaluate the outcome of this study, such as comparing
clinical outcomes of TIPS vs. CARTO and longer-term follow-
up of CARTO.
In summary, with our preliminary outcomes data, including
efficacy and complications, CARTO appears to be a safe and
effective treatment option for the treatment of portal hyperten-
sive variceal bleeding, including gastric, duodenal, jejunal,
stomal, and rectal varices. The effectiveness appears to be
comparable to previously reported modified BRTO and
traditional BRTO.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Conventional balloon-occluded retrograde transvenous
obliteration (BRTO) is shown to have outstanding outcomes
as a treatment option for portal hypertensive variceal
bleeding, including gastric variceal bleeding (GVB).
✓ Conventional BRTO requires an indwelling balloon and
toxic sclerosing agent to obliterate the gastric variceal (GV)
and gastrorenal shunt.
✓ Both indwelling balloon and sclerosing agents are closely
associated with some of the major complications of BRTO,
including symptomatic pulmonary embolism, renal toxicity,
and permanent portal and renal thrombosis.
WHAT IS NEW HERE
✓ This is the first description of modified BRTO/coil-assisted
retrograde transvenous obliteration (CARTO) using coils as
a primary occlusion material.
✓ CARTO does not require an indwelling balloon or toxic
sclerosing agent. Therefore some of the major
complications associated with conventional BRTO are
minimized.
✓ CARTO is an improved BRTO with a single-day procedure
(no indwelling balloon).
✓ The sample is small, but its preliminary results shows that
CARTO is effective in treating GV bleeding with a safer
complication profile.
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